StockNews.AI
NPCE
StockNews.AI
74 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

1. Pomerantz LLP is investigating investor claims against NeuroPace. 2. Investigation concerns potential securities fraud and unlawful practices by NeuroPace executives. 3. NeuroPace's recent study results were not statistically significant for primary effectiveness. 4. Stock fell 28.39% to $12.66 per share following the study announcement. 5. Pomerantz has a history of recovering large damages for class action victims.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock drop following disappointing trial results indicates loss of investor confidence, reminiscent of other biotech firms facing similar crises.

How important is it?

The investigation indicates serious legal risks for NPCE, potentially leading to extended liability and drop in stock price.

Why Short Term?

The immediate concern revolves around the ongoing investigation and potential legal outcomes that could affect stock price in the near term, typical in the wake of bad news for biotech companies.

Related Companies

BCRXAVXLSNYVRTX
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether NeuroPace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, 2025, NeuroPace issued a press release “announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).”  The press release disclosed that “[t]he study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group.”  On this news, NeuroPace’s stock price fell $5.02 per share, or 28.39%, to close at $12.66 per share on May 27, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News